Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial
Sitagliptin, ein DPP-4-Inhibitor, fördert die Heilung des diabetischen Fußulkus: eine randomisierte kontrollierte Studie
Journal of Diabetes · 2025-09 · 17 (9)
DOI: 10.1111/1753-0407.70156 ↗Auf einen Blick
In einer randomisierten Studie heilte das diabetische Fußulkus unter Sitagliptin zusätzlich zur Standardtherapie besser als unter Standardtherapie allein. Es traten keine sitagliptinassoziierten unerwünschten Ereignisse auf.
Fragestellung
Wirkt Sitagliptin bei diabetischen Fußulzera zusätzlich zur Standardtherapie auf die Ulkusheilung?
Methode
Randomisierte, offene klinische Studie; 62 Teilnehmende, je 31 pro Gruppe; Sitagliptin 100 mg 1-mal täglich plus Standardtherapie vs. Standardtherapie allein.
Ergebnisse
62 Teilnehmende, 31 pro Gruppe; 1 Verlust pro Gruppe. Unter Sitagliptin stärkere Ulkusflächenreduktion und bessere Heilung (p < 0,05), mehr CD34+ EPCs und höhere SDF-1α-Werte (je p < 0,05); HbA1c ohne Unterschied.
Schlussfolgerung der Autor:innen
Sitagliptin könnte die Heilung diabetischer Fußulzera unabhängig von der Glukosesenkung fördern, möglicherweise über mehr CD34+ EPCs im peripheren Blut.
Kernaussagen
- Bessere Ulkusheilung unter Sitagliptin als unter Standardtherapie
- Mehr CD34+ EPCs und höhere SDF-1α-Werte unter Sitagliptin
- Keine sitagliptinassoziierten unerwünschten Ereignisse berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes, online erschienen am 15.09.2025. Verfasst von Wei Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Dipeptidyl-Peptidase IV Inhibitors, Diabetic Foot, Wound Healing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Bureau of Sichuan Province, Health Commission of Sichuan Province, 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Background
This randomized controlled trial (RCT) was designed to evaluate the effects of sitagliptin on diabetic foot ulcers (DFUs).
Methods
This was a randomized, open‐label clinical trial. The participants were assigned to either the control group, which received standard conventional therapy alone, or the sitagliptin treatment group, which received an oral administration of sitagliptin (100 mg once daily) in conjunction with standard conventional therapy. The primary endpoints were the ulcer healing rate and adverse reactions. The secondary endpoints included the time to ulcer healing, peripheral blood CD34+ endothelial progenitor cells (EPCs) count, serum levels of stromal cell‐derived factor‐1α (SDF‐1α), and glycosylated hemoglobin A1c (HbA1c).
Results
A total of 62 subjects were enrolled in this trial, with 31 individuals assigned to each group. One participant from each group was lost to follow‐up. Posttrial analysis revealed that, compared with the control group, the sitagliptin group demonstrated a significantly greater reduction in ulcer area and improved efficacy in terms of ulcer healing ( p < 0.05). Although not statistically significant ( p = 0.071), the sitagliptin group also tended to have a shorter ulcer healing time. Additionally, the sitagliptin group presented significantly greater numbers of CD34+ EPCs and higher SDF‐1α levels compared to the control group ( p < 0.05). No statistically significant difference in HbA1c levels was observed between the two groups ( p > 0.05). No adverse events associated with sitagliptin treatment were reported.
Conclusions
The DPP‐4 inhibitor sitagliptin may facilitate the healing of DFUs independent of its glucose‐lowering effects, potentially by enhancing the mobilization of CD34 + EPCs in peripheral blood. Trial Registration: Registration number: ChiCTR 2000029230, Approval date: 2020/01/19
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
- Health Management Center, General Practice Center, West China Hospital, Chengdu, China.
- Innovation Research Center for Diabetic Foot, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Endocrinology and Metabolism, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, China.
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
- Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Xingwu Ran
Förderung
- Science and Technology Bureau of Sichuan Province
- Health Commission of Sichuan Province
- 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University
- 1.3.5 Project of Center for High Altitude Medicine, West China Hospital, Sichuan University
Zitieren
APA
Gao, W., Chen, D., He, H., Jiang, N., Chen, L., & Ran, X. (2025). Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. Journal of Diabetes, 17(9). https://doi.org/10.1111/1753-0407.70156
Vancouver
Gao W, Chen D, He H, Jiang N, Chen L, Ran X. Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. Journal of Diabetes. 2025;17(9). doi:10.1111/1753-0407.70156
BibTeX
@article{Gao2025,
author = {Gao, Wei and Chen, Dawei and He, Hua and Jiang, Nenggang and Chen, Lihong and Ran, Xingwu},
title = {Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial},
journal = {Journal of Diabetes},
year = {2025},
volume = {17},
number = {9},
doi = {10.1111/1753-0407.70156}
}
EUVIMED